Relevant bibliographies by topics / Pdt photodynamic therapy imaging cancer

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Book chapters
  4. Conference papers
  5. Reports

Academic literature on the topic 'Pdt photodynamic therapy imaging cancer'

Author: Grafiati
Published: 9 March 2023
Last updated: 10 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Pdt photodynamic therapy imaging cancer.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Pdt photodynamic therapy imaging cancer"

1

Li, Ziwei, Fan Yang, Di Wu, Yanhong Liu, Yang Gao, Haichen Lian, Hongxin Zhang, Zhibin Yin, Aiguo Wu, and Leyong Zeng. "Ce6-Conjugated and polydopamine-coated gold nanostars with enhanced photoacoustic imaging and photothermal/photodynamic therapy to inhibit lung metastasis of breast cancer." Nanoscale 12, no. 43 (2020): 22173–84. http://dx.doi.org/10.1039/d0nr05386d.

Full text
Abstract:
Chlorin e6 (Ce6)-conjugated and polydopamine (PDA)-coated gold nanostar (AuNS) nanocomposites (AuNSs@PDA-Ce6) with enhanced photoacoustic (PA) imaging, photothermal therapy (PTT) and photodynamic therapy (PDT) to inhibit lung metastasis of breast cancer.
APA, Harvard, Vancouver, ISO, and other styles
2

Banerjee, Shramana M., Soha El-Sheikh, Anmol Malhotra, Charles A. Mosse, Sweta Parker, Norman R. Williams, Alexander J. MacRobert, Rifat Hamoudi, Stephen G. Bown, and Mo R. S. Keshtgar. "Photodynamic Therapy in Primary Breast Cancer." Journal of Clinical Medicine 9, no. 2 (February 10, 2020): 483. http://dx.doi.org/10.3390/jcm9020483.

Full text
Abstract:
Photodynamic therapy (PDT) is a technique for producing localized necrosis with light after prior administration of a photosensitizing agent. This study investigates the nature, safety, and efficacy of PDT for image-guided treatment of primary breast cancer. We performed a phase I/IIa dose escalation study in 12 female patients with a new diagnosis of invasive ductal breast cancer and scheduled to undergo mastectomy as a first treatment. The photosensitizer verteporfin (0.4 mg/kg) was administered intravenously followed by exposure to escalating light doses (20, 30, 40, 50 J; 3 patients per dose) delivered via a laser fiber positioned interstitially under ultrasound guidance. MRI (magnetic resonance imaging) scans were performed prior to and 4 days after PDT. Histological examination of the excised tissue was performed. PDT was well tolerated, with no adverse events. PDT effects were detected by MRI in 7 patients and histology in 8 patients, increasing in extent with the delivered light dose, with good correlation between the 2 modalities. Histologically, there were distinctive features of PDT necrosis, in contrast to spontaneous necrosis. Apoptosis was detected in adjacent normal tissue. Median follow-up of 50 months revealed no adverse effects and outcomes no worse than a comparable control population. This study confirms a potential role for PDT in the management of early breast cancer.
APA, Harvard, Vancouver, ISO, and other styles
3

Yoshida, Tomoyuki, Harubumi Kato, Tetsuya Okunaka, Tetsuo Saeki, Shinya Ohashi, Tadao Okudaira, A. Masaji Lee, et al. "Photodynamic Therapy for Head and Neck Cancer." Diagnostic and Therapeutic Endoscopy 3, no. 1 (January 1, 1996): 41–51. http://dx.doi.org/10.1155/dte.3.41.

Full text
Abstract:
Photodynamic therapy (PDT) is a recently developed treatment involving the use of a photosensitizer and low power light, usually from a laser, to selectively destroy tumor cells. At present, we perform PDT for head and neck cancer using argon or excimer dye lasers with hematoporphyrin derivative as a photosensitizer. This study attempted to assess the utility and safety of PDT and to investigate the long-term outcome. All 24 patients had squamous cell carcinoma: 15 with laryngeal, 5 with lingual or oral, and 4 with pharyngeal cancer and were treated by PDT. Data were obtained from records from February 1988 through April 1995. After PDT, 12 of 15 laryngeal cancer patients were classified as having a complete remission (CR), as were 2 of the 5 lingual or oral and one of the 4 pharyngeal cancer patients. The patients were followed for 8 to 153 months. The longest duration of CR in patients treated by PDT alone was 148 months. Photosensitivity was experienced by all patients, but required no treatment. Liver, kidneys, and bone marrow showed no abnormal values. There were no clinically relevant adverse reactions, and patients with severe complications due to other types of treatment and elderly patients were also treated safely with this therapy.
APA, Harvard, Vancouver, ISO, and other styles
4

Nanashima, Atsushi, Masahide Hiyoshi, Naoya Imamura, Koichi Yano, Takeomi Hamada, and Kengo Kai. "Recent Advances in Photodynamic Imaging and Therapy in Hepatobiliary Malignancies: Clinical and Experimental Aspects." Current Oncology 28, no. 5 (October 11, 2021): 4067–79. http://dx.doi.org/10.3390/curroncol28050345.

Full text
Abstract:
The therapeutic and diagnostic modalities of light are well known, and derivative photodynamic reactions with photosensitizers (PSs), specific wavelengths of light exposure and the existence of tissue oxygen have been developed since the 20th century. Photodynamic therapy (PDT) is an effective local treatment for cancer-specific laser ablation in malignancies of some organs, including the bile duct. Although curability for extrahepatic cholangiocarcinoma is expected with surgery alone, patients with unresectable or remnant biliary cancer need other effective palliative therapies, including PDT. The effectiveness of PDT for cholangiocarcinoma has been reported experimentally or clinically, but it is not the standard option now due to problems with accompanied photosensitivity, limited access routes of irradiation, tumor hypoxia, etc. Novel derivative treatments such as photoimmunotherapy have not been applied in the field hepatobiliary system. Photodynamic diagnosis (PDD) has been more widely applied in the clinical diagnoses of liver malignancies or liver vascularization. At present, 5-aminolevulinic acid (ALA) and indocyanine green (ICG) dyes are mainly used as PSs in PDD, and ICG has been applied for detecting liver malignancies or vascularization. However, no ideal tools for combining both PDD and PDT for solid tumors, including hepatobiliary malignancies, have been clinically developed. To proceed with experimental and clinical trials, it is necessary to clarify the effective photosensitive drugs that are feasible for photochemical diagnosis and local treatment.
APA, Harvard, Vancouver, ISO, and other styles
5

Shrestha, Rajeev, Hyun Ji Lee, Junmo Lim, Pallavi Gurung, Til Bahadur Thapa Magar, Young-Tak Kim, Kija Lee, Seulgi Bae, and Yong-Wan Kim. "Effect of Photodynamic Therapy with Chlorin e6 on Canine Tumors." Life 12, no. 12 (December 14, 2022): 2102. http://dx.doi.org/10.3390/life12122102.

Full text
Abstract:
This work aims to prepare pure Chlorin e6 (Ce6) and establish Ce6-mediated photodynamic therapy (Ce6-PDT) as a better therapy option for canine tumors as well as mouse tumor models. Five dogs suffering from various cancers were treated with Ce6-PDT from one to several times. After receiving the Ce6 (2.5 mg/kg) for 3 h, tumors were illuminated superficially or interstitially with 660 nm light. Two dogs underwent Ce6-guided fluorescence imaging by photodynamic diagnosis (PDD). Cell proliferation and apoptosis were detected by the 4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay and western blot assay, respectively. Ce6-PDT efficacy was also determined using melanoma and pancreatic cancer mouse models. Two veterinary patients with mammary carcinoma and histiocytic sarcoma had their tumors significantly diminished and showed improved health after receiving Ce6-PDT. Moreover, in the cases of canine tumors, the adjunctive use of Ce6-PDD revealed cancers that were not visible with white light viewing and provided a visual contrast from surrounding tissues. Also, in vivo, Ce6-PDT remarkably reduced melanoma and pancreatic tumors in the mouse model. These findings could pave the way for a better understanding of the underlying processes of Ce6-PDT, making it an effective and safe candidate for use in human and veterinary applications to abolish various cancers.
APA, Harvard, Vancouver, ISO, and other styles
6

Mimura, Seishiro, Hiroyuki Narahara, Toru Otani, and Shigeru Okuda. "Progress of Photodynamic Therapy in Gastric Cancer." Diagnostic and Therapeutic Endoscopy 5, no. 3 (January 1, 1999): 175–82. http://dx.doi.org/10.1155/dte.5.175.

Full text
Abstract:
Progress of photodynamic therapy (PDT) in gastric cancer and the clinical outcome are described in this paper. (1) We included the whole lesion and a 5 mm margin in the field for irradiation. Marking by injection of India-ink showing the irradiation field was performed beforehand. (2) We established the standard light dose to be 90 J/cm2 for an argon dye laser and 60 J/cm2 for a pulse wave laser. (3) The size of cancerous lesion curable by PDT was expanded from 3 cm in diameter, i.e. 7 cm2 in area to 4 cm in diameter, i.e. 13 cm2 by employing a new excimer dye laser model, which could emit 4mJ/pulse with 80 Hz pulse frequency. (4) The depth of cancer invasion which could be treated by PDT was increased from about 4 mm, i.e. the superficial part of the submucosal layer (SM-1) to more than 10 mm in depth, i.e. the proper muscular layer. These improvements owe much to the pulse laser, the photodynamic action induced by which permits deeper penetration than that of a continuous wave laser. (5) We employed a side-viewing fiberscope for gastric PDT to irradiate the lesion from an angle of 90°. (6) We designed a simple cut quartz fiber for photoradiation with a spiral spring thickened toward the end. (7) We developed an endoscopic device for photoradiation in PDT which achieves accurate and efficient irradiation. As a result of these improvements a higher cure rate was obtained even with a lower light dose of irradiation.
APA, Harvard, Vancouver, ISO, and other styles
7

Sutedja, Tom G. "Photodynamic Therapy in Advanced Tracheobronchial Cancers." Diagnostic and Therapeutic Endoscopy 5, no. 4 (January 1, 1999): 245–51. http://dx.doi.org/10.1155/dte.5.245.

Full text
Abstract:
Photodynamic therapy (PDT) has been introduced in the early eighties for treating patients with malignancies in the tracheobronchial tract. After intravenous injection of the photosensitizers, the tumor area in the tracheobronchial tree is illuminated bronchoscopically using a laser fiber to transmit light of a specific wavelength during the procedure. Secondary tissue necrosis ensues, because of the thrombosis of the tumor vasculature leading to late tissue hypoxia. Ample data have shown that PDT is effective to obtain full depth tissue necrosis with relative sparing of the normal tissue. Local tumor control can be achieved. Competitive endoscopic techniques such as lasers and electrocautery are applicable to debulk tumor in a less selective but more immediate manner. Skin photosensitivity is a potential morbidity of PDT, especially in using the first generation photosensitizers. This limits its palliative potential. More selective and more phototoxic sensitizers in combination with the use of portable diode laser, may improve the clinical usefulness of PDT in the management of lung cancer patients. However, cost-effectiveness studies comparing PDT and other local bronchoscopic treatment modalities such as thermal lasers, electrocautery, cryotherapy, brachytherapy, whether or not in addition to external radiotherapy and chemotherapy, should be conducted to define its definite role in the palliative treatment of advanced obstructive bronchial cancers.
APA, Harvard, Vancouver, ISO, and other styles
8

Okunaka, Tetsuya, Toshimitsu Hiyoshi, Kinya Furukawa, Hideki Yamamoto, Takaaki Tsuchida, Jitsuo Usuda, Hideo Kumasaka, Junzou Ishida, Chimori Konaka, and Harubumi Kato. "Lung Cancers Treated With Photodynamic Therapy and Surgery." Diagnostic and Therapeutic Endoscopy 5, no. 3 (January 1, 1999): 155–60. http://dx.doi.org/10.1155/dte.5.155.

Full text
Abstract:
Laser endoscopic surgery, especially the effectiveness of photodynamic therapy (PDT) using Photofrin as a photosensitizer, has now achieved a status as effective treatment modality for lung cancer. Twenty-six lung cancer patients received the preoperative PDT for the purpose of either reducing the extent of resection or increasing operability. Bronchoscopical PDT is performed with topical anesthesia approximately 48 h after the intravenous injection of 2.0 mg/kg body weight of Photofrin. Operation was performed 2–9 weeks after initial PDT. The initial purpose of PDT, i.e. either to reduce the extent of resection or convert inoperable disease to operable status, was achieved in 22 out of 26 patients treated. The survival rate of T3 (main bronchus invasion) cases treated by surgery alone increased significantly from 50.9% to 60.0% with the application of preoperative PDT. This remarkable result may imply that this new option of PDT as preoperative laser irradiation may contribute to the management of advanced lung malignancy.
APA, Harvard, Vancouver, ISO, and other styles
9

Zhu, Ya-Xuan, Hao-Ran Jia, Zhan Chen, and Fu-Gen Wu. "Photosensitizer (PS)/polyhedral oligomeric silsesquioxane (POSS)-crosslinked nanohybrids for enhanced imaging-guided photodynamic cancer therapy." Nanoscale 9, no. 35 (2017): 12874–84. http://dx.doi.org/10.1039/c7nr02279d.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Zhang, Yang, Cai-Xia Wang, and Shi-Wen Huang. "Aggregation-Induced Emission (AIE) Polymeric Micelles for Imaging-Guided Photodynamic Cancer Therapy." Nanomaterials 8, no. 11 (November 7, 2018): 921. http://dx.doi.org/10.3390/nano8110921.

Full text
Abstract:
Photodynamic therapy (PDT) is a noninvasive treatment for selectively killing malignant tumor cells. The photosensitizer is a necessary component of photodynamic nanomedicine. Many efforts have been made to develop new photosensitizers for efficient cancer photodynamic therapy. In this work, we report a novel nano photosensitizer, polymeric micelles (AIE-M) with aggregation induced emission characteristic, for photodynamic cancer therapy. AIE-M with sub-20 nm particle size is prepared by the self-assembly of salicylaldazine-incorporated amphiphilic polymer (AIE-1), which can produce reactive oxygen species (ROS) with light irradiation in solution. After uptake by cancer cells, AIE-M can specially sojourn in plasma membranes of cancer cells at the early stage and predominantly accumulate in the mitochondria of cancer cell at the late stage. The phototoxicity of AIE-M, resulting from the generation of intracellular ROS with light irradiation, can efficiently cause cancer cells death by apoptosis and necrosis. The advantages of AIE-M as a nano photosensitizer include the small size, highly colloidal stability in the process of preparation and storage, and high cell penetration. The ultra-low Critical Micelle Concentration (CMC) of AIE-1, negligible dark toxicity and super phototoxicity of AIE-M suggest its promising potential for image-guided PDT.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Pdt photodynamic therapy imaging cancer"

1

SALICE, PATRIZIO. "Towards cancer treatment: synthesis and characterization of photoactive theranostic nanoclinics." Doctoral thesis, Università degli Studi di Milano-Bicocca, 2009. http://hdl.handle.net/10281/10350.

Full text
Abstract:
This thesis describes the synthesis, the photophysical, photochemical and biological characterization of some organic aromatic heterocycle derivatives and their theranostical applications to cancer treatment. Although the topic thus falls within the general area of photomedicine, the approach adopted here takes advantage of the strong interdisciplinary character of a materials science PhD course to explore an original perspective in the molecular design of novel photosensitizers and fluorescent probes in the fight against cancer. In the initial part of this work, we explore the synthetic accessibility of squaraine dyes candidates as second generation sensitizers for Photodynamic Therapy (PDT). This well-established treatment involves the insurgence of citotoxic species in the cellular environment after irradiation of a dye with visible light. Typically, the sensitizer excited triplet state generated after irradiation can induce the formation of singlet oxygen, O2(1δg), the lowest excited state of molecular oxygen, and/or reactive oxygen species (ROS). It is generally accepted that production of sufficient quantities of O2(1δg) and/or ROS, can perturb cellular processes and ultimately cause cell death. Among the large number of known photosensitizers, squaraine dyes (1,3-dicondensation products of squaric acid and electron rich molecules) possess an intense one-photon absorption in the transparency window of biological tissues. Furthermore, squaraines possess an exceedingly strong two photon absorption enabling for their use at the wavelengths relevant for clinical applications (644 nm and 806 nm, respectively). We herein report multiple strategies aimed at the improvement of the reaction yield, of byproducts removal and of time sparing. Because of the many demanding requirements of modern PDT sensitizers, I felt important to investigate with greater effort the photophysical behavior of heterocycle-based π-extended polymethine dyes to get further insight into the possible oxygen-mediated mechanism leading to cellular phototoxicity. To this aim, we have measured singlet oxygen yields (Φ∆), fluorescence quantum yield (Φf), triplet yield (ΦT) and singlet oxygen rates (kq) in toluene and acetonitrile and cyclic voltammetry in dichloromethane. All of the data collected point out that these electronrich polymethine compounds have a strong affinity with molecular oxygen leading to the formation of a charge transfer encounter complex. This results in low singlet oxygen yields and high singlet oxygen rates for these dyes. To elucidate the photodamaging mechanism I designed simple photochemical experiments: firstly, I analyzed the photobleaching behavior of a benzothiazole-based squaraine by GC-MS and I observed the formation of two carbonyl compounds in accordance with a photooxygenation of the enaminic bond; secondly, I studied the product distribution of the reaction between light, squaraines and biologically relevant targets (i.e., limonene, cholesterol, and methyl linoleate) pointing out the presence of a radical chain of oxidative events. Consistently with the photophysical characterization, I established that the encounter complex between squaraine and molecular oxygen could evolve either by photooxygenation of the enaminic bond in the squaraine backbone or by ROS production leading to lipid peroxidation that culminate in cell death by a Type I mechanism. Indeed, the in-depth biological evaluation of two benzothiazole-based squaraine dyes showed that these dyes internalized in lipid vesicles in the cytoplasm and, although they are non-significantly cytotoxic in the dark, they promote a strong dose-dependent phototoxic effect in four different cancer cells after irradiation. In HeLa and MCF-7 cells 3.1c and 3.30, through their hydrocarbon chain substitutions, associate to the membranes and induce lipid peroxidation, as expected from the photophysical and photochemical study, causing cell death primarily by necrosis A challenge that occurs when dealing with photosensitizers is the way they are solubilized and specifically delivered to the biological target. In order to overcome thisp roblem, I have shown how the wide flexibility of the squaraine structure provides a powerful tool aimed at the improvement of bioavailability. In particular, we designed and synthesized a library of squaraine dyes functionalized with ionic groups (sulfonate), alkyl groups and biologically relevant groups (e.g. cholesterol), apt to be delivered in the free form, into liposomes or into low-density lipoproteins (LDL). Through photophysical and photochemical characterization, estimate of singlet oxygen generation efficiencies, subcellular localization and phototoxicity studies in cancer cell lines, we obtained encouraging results about the theranostical capabilities of some of these squaraine dyes, opening the way for their use in cancer-related PDT applications. To further validate the previous observations, I designed an experiment aim to activate the production of ROS in a family of cyanine dyes. I chose to engineer the progenitor Cy5 at the molecular level and increase its photooxidation capabilities by exploiting the effect plays by heteroaryl meso-substituents on the cyanine oxidation potential. By monitoring the degradation of 1,3-diphenylisobenzofuran (DPBF) after irradiation of a sensitizer in the presence of oxygen in solution I showed that it is possible to control the redox behavior, hence the ROS production, by modulating the extent of electron density pulled by the chromophoric side-group in the meso position and boost the photooxidative capability in the series of cyanine derivatives investigated. Moreover, I report on the synthesis, characterization and spectroscopic study both in solution and ex vivo of seven quadrupolar eteroaryl compounds which have been designed to be promising candidates as tumor-specific fluorescent molecular probes. Basic photophysical characteristics of these dyes, their subcellular localization in human umbilical vein endothelial cells (HUVEC), and their hydrophilicity based on logP values have provided in-depth insight into the processes that lead to accumulation in either mitochondria or lysosomes. I have also succeeded in recording its fluorescence spectrum ex vivo, obtaining further information about the interaction between this heteroaromatic dicationic dye and the biological environment.
APA, Harvard, Vancouver, ISO, and other styles
2

Kulyk, Olena. "Light-tissue interactions for developing portable and wearable optoelectronic devices for sensing of tissue condition, diagnostics and treatment in photodynamic therapy (PDT)." Thesis, University of St Andrews, 2016. http://hdl.handle.net/10023/13199.

Full text
Abstract:
This thesis presents the development and in-vivo applications of wearable and portable devices for the investigation of light interaction with tissue involved in Photodynamic therapy (PDT) and during contraction of muscles. A hand-held device and a clinical method were developed for time course in-vivo imaging of the fluorescence of the photosensitizer Protoporphyrin IX (PpIX) in healthy and diseased skin with the aim to guide improvement of PDT protocols. The device was used in a small clinical study on 11 healthy volunteers and 13 patients diagnosed with non-melanoma skin cancer (NMSC). Two types of PpIX precursors were administered: Ameluz gel and Metvix® cream. The fluorescence was imaged with a 10 minute time step over three hours which was the recommended metabolism time before commencing PDT treatment at Ninewells Hospital, Dundee. The fluorescence time course was calculated by integrating the areas with the highest intensity. The fluorescence continued to grow in all subjects during the three hours. The time course varied between individuals. There was no statistical significance between either healthy volunteers or patients in Ameluz vs Metvix® groups; nor was there statistical difference between the three lesions groups (Actinic keratosis (AK) Ameluz vs AK Metvix® vs Basal cell carcinoma (BCC) Metvix®). The p-value was larger than 0.05 in a two sample t-test with unequal variances for all the groups. However, there was strong body site dependence between the head & neck compared to the lower leg & feet, or the trunk & hands body site groups (p-value < 0.01). One of the possible explanations for this was temperature and vasculature variation in skin at different body sites: the temperature is higher and the vasculature structure is denser at the head and the neck compared to the lower leg or the trunk. The temperature was not measured during the study. So in order to support this hypothesis, typical skin temperatures at the lesion sites were taken from the IR thermal images of healthy skin available in literature. PpIX fluorescence had a positive correlation to temperature. If this hypothesis is true, it will be highly important to PDT treatment. Increasing the temperature could speed up the metabolism and reduce the waiting time before starting the treatment; ambient temperature should be taken into account for daylight PDT; cooling air as pain management should be administered with caution. Potential improvements for wearable PDT light sources were investigated by modelling light transport in skin for the current LED-based Ambulight PDT device, a commercial OLED for future devices and a directional OLED developed in the group. The optical models were implemented in commercial optical software (with intrinsic Monte Carlo ray tracing and Henyey-Greenstein scattering approximation) which was validated on diffuse reflectance and transmittance measurements using in-house made tissue phantoms. The modelling was applied to investigate the benefits from diffusive and forward scattering properties of skin on light transmission in treatment light sources. 1 mm thick skin can only compensate approximately 10% of non-uniform irradiance. It means that uniform illumination is crucial for the treatment light sources. Forward scattering in skin showed a 10% improved light transmission from a collimated emission compared to a wide angle Lambertian emission. However, depth-dependent transmission measurements of directional vs Lambertian emission from organic light emitting films (a nano-imprinted grating was fabricated to provide directional emission in one of the films), collimated vs diffused HeNe laser light through fresh porcine skin did not show the expected improvement. This could be explained by skin roughness which was previously found to change the optical properties and may also affect light coupling. The modelling was applied to guide an optical design of another wearable device – a muscle contraction sensor. Muscle is fibrous and because of that scatters light differently in different directions. The sensor detects the change in backscattered light in parallel and perpendicular directions with respect to muscle fibres. The sensor was implemented on a wearable bandage on fully flexible substrate with flexible OLED and organic photodiodes. The major advantages of organic optoelectronic sensing compared to conventional electromyography (EMG) sensors are the ability to distinguish two types of contractions (isotonic and isometric), insensitivity to electromagnetic interference and the absence of an immune response due to non-invasive electrode-free sensing. Optical modelling was performed to understand the operation of the sensor. A 3D anisotropic optical model of scattering in muscle was created by geometrical manipulations with the standard Henyey-Greenstein scattering volumes. The penetration depth from the Super Yellow OLED was found to be 20-25 mm; the optimal separation between the source and the detector was found to be 20 mm. This distance provided a still detectable signal along with the best discrimination between the two backscatterings. When a 2 mm thick layer of skin and a 2 mm thick layer of adipose tissue were added to the model, the signal was hugely diffused. The discrimination between the two backscatterings decreased by three orders of magnitude, the penetration depth in muscle was reduced, and the intensity of the signal dropped down but was still detectable. With 5 mm thick adipose tissue and 2 mm thick skin the signal was too diffused and interacted with very shallow layers of muscle which approached the limits of the optical sensing of muscle activity.
APA, Harvard, Vancouver, ISO, and other styles
3

Bishop, Steven Michael. "Preparation and properties of phthalocyanine sensitisers for photodynamic therapy (PDT)." Thesis, Imperial College London, 1993. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.366093.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Shao, Ning. "Sensing, imaging and photodynamic therapy of cancer." Access to citation, abstract and download form provided by ProQuest Information and Learning Company; downloadable PDF file, 73 p, 2007. http://proquest.umi.com/pqdweb?did=1400965061&sid=14&Fmt=2&clientId=8331&RQT=309&VName=PQD.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Walther, Jan, Stanislas Schastak, Sladjana Dukic-Stefanovic, Peter Wiedemann, Jochen Neuhaus, and Thomas Claudepierre. "Efficient photodynamic therapy on human retinoblastoma cell lines." Universitätsbibliothek Leipzig, 2014. http://nbn-resolving.de/urn:nbn:de:bsz:15-qucosa-148182.

Full text
Abstract:
Photodynamic therapy (PDT) has shown to be a promising technique to treat various forms of malignant neoplasia. The photodynamic eradication of the tumor cells is achieved by applying a photosensitizer either locally or systemically and following local activation through irradiation of the tumor mass with light of a specific wavelength after a certain time of incubation. Due to preferential accumulation of the photosensitizer in tumor cells, this procedure allows a selective inactivation of the malignant tumor while sparing the surrounding tissue to the greatest extent. These features and requirements make the PDT an attractive therapeutic option for the treatment of retinoblastoma, especially when surgical enucleation is a curative option. This extreme solution is still in use in case of tumours that are resistant to conventional chemotherapy or handled too late due to poor access to medical care in less advanced country. In this study we initially conducted in-vitro investigations of the new cationic water-soluble photo sensitizer tetrahydroporphyrin-tetratosylat (THPTS) regarding its photodynamic effect on human Rb-1 and Y79 retinoblastoma cells. We were able to show, that neither the incubation with THPTS without following illumination, nor the sole illumination showed a considerable effect on the proliferation of the retinoblastoma cells, whereas the incubation with THPTS combined with following illumination led to a maximal cytotoxic effect on the tumor cells. Moreover the phototoxicity was lower in normal primary cells from retinal pigmented epithelium demonstrating a higher phototoxic effect of THPTS in cancer cells than in this normal retinal cell type. The results at hand form an encouraging foundation for further in-vivo studies on the therapeutic potential of this promising photosensitizer for the eyeball and vision preserving as well as potentially curative therapy of retinoblastoma.
APA, Harvard, Vancouver, ISO, and other styles
6

Clarke, Oliver J. "Isothiocyanato porphyrins for bioconjugation : synthesis and applications in targeted photochemotherapy and fluorescence imaging." Thesis, University of Essex, 2001. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.327076.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Fok, Wanyiu. "Theranostic porphyrin-cyclen gadolinium complex for photodynamic therapy and magnetic resonance imaging." HKBU Institutional Repository, 2019. https://repository.hkbu.edu.hk/etd_oa/706.

Full text
Abstract:
Photodynamic therapy (PDT) and Magnetic resonance imaging (MRI) are two techniques used in therapeutic and diagnostic purpose respectively. PDT can selectively kill the cancer cells by utilizing light and photosensitizer, while MRI provides invasive imaging on our interior bodies. If these two techniques combine, the probe can act as both PDT and MRI agent at the same time. This theranostic agents can bring great efficiency in the cancer treatment. In this project, a porphyrin-cyclen gadolinium based dual functions bio-probe, PZnGdL, is designed for diagnostic and photodynamic therapeutic functions. PZnGdL demonstrated a great T1 signal enhancement for MRI, in which its T1 relaxivity is 15.06 mM-1s-1 (at 1.4T, 37oC). The T1 relaxivity is five-fold higher than the clinically approved MRI contrasting agent Gd-DOTA, (2.92 at 1.4T, 37oC). Furthermore, PZnGdL exhibits low dark toxicity and high photocytotoxicity. Therefore, its photodynamic therapeutic index (PDI) in HeLa cells is as high as 1348 upon 1 J/cm2 light irradiation. Results from the present study show that PZnGdL is an effective photodynamic therapy agent as well as a safe and promising MRI contrasting agent.
APA, Harvard, Vancouver, ISO, and other styles
8

Tsao, Max. "Synthesis and Characterization of Novel Ru(II) Dipyrrin Complexes for Use as Photodynamic Therapy Agents in Cancer Treatments." University of Dayton / OhioLINK, 2019. http://rave.ohiolink.edu/etdc/view?acc_num=dayton156155545171778.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Nazarenko, Iuliia. "Lanthanide based dendrimers for photodynamic therapy and biological optical imaging." Thesis, Orléans, 2015. http://www.theses.fr/2015ORLE2074.

Full text
Abstract:
La thérapie photodynamique (PDT) est une méthode de lutte contre le cancer basée sur l’utilisation de la lumière et d’un composé sensible à la lumière, appelé photosensibilisateur (PS). Le PS absorbe la lumière et, en présence d’oxygène, engendre la production des dérivés réactifs de l'oxygène (DRO), lesquels sont toxiques et provoquent la régression de la tumeur. La limitation principale des PSs utilisés dans les tests cliniques est leur faible sélectivité envers les tissus cancéreux. Le but principal de ce projet est de créer des agents multifonctionnels combinant sur une même molécule l’activité PDT, la vectorisation et l’imagerie optique proche infrarouge. Dans cette région du spectre optique, les cellules possèdent une faible autofluorescence, et la lumière proche infrarouge pénètre plus profondément dans les tissus biologiques que la lumière visible. Nous proposons ici de modifier une structure dendrimérique de type poly(amidoamine) de génération 3, en tant que plateforme polyvalente. En effet, ce dernier possède trente-deux groupes terminaux qui peuvent être facilement substitués par des PSs. De plus, cette macromolécule peut complexer dans ses cavités jusqu’à 8 cations lanthanides émettant dans le proche infrarouge. Quatre nouveaux ligands dendrimère ont été synthétisés avec différents PSs tels que des dérivés de naphtalimide, d’anthraquinone et de tétraphénylporphyrine. De plus, le naphtalimide a été couplé avec des groupes dérivés de l’acide folique pour assurer la vectorisation envers les tissus cancéreux. Les complexes de lanthanide émettant dans le proche infrarouge ont été préparés pour chaque dendrimère. La caractérisation des performances des différents complexes a été réalisée. La production de DRO et la présence de complexes d’Yb(III) a été démontrée dans les cellules HL60. Les dendrimères modifiés par les groupes anthraquinone et tétraphénylporphyrine en tant que PS, ont montré, dans les cellules vivantes, une émission proche infrarouge lorsqu’ils sont sous la forme de complexe d’Yb(III). Les résultats obtenus montrent que les complexes de lanthanides formés avec des ligands dendrimères peuvent servir comme des agents de PDT et des rapporteurs luminescents proche infrarouge in cellulo
PDT is a cancer treatment that uses the combination of a nontoxic photoactivated molecule (photosensitizer), an appropriate source of light excitation and molecular oxygen to generate reactive oxygen species (ROS) leading to the decrease of size or to the destruction of tumors. However, the PDT efficiency of currently used drugs is limited by the selectivity for the cancer tissue. The main goal of this work is to develop a multifunctional agent which combines a PDT activity, a tumor targeting and near-infrared (NIR) optical imaging. The use of reporters that absorb at low energy is justified by low tissue autofluorescence and high tissue penetration depth in the NIR spectrum window. For this purpose, we have chosen the generation-3 poly(amidoamine) dendrimers as a versatile platform. Such macromolecules can incorporate eight NIR emitting lanthanide ions inside their branches forming species with thirty-two end groups at the periphery that can be substituted by suitable photosensitizers. Four new dendrimer ligands were synthesized with different photosensitizers, such as derivatives of naphthalimide, anthraquinone, and porphyrin. In addition the naphthalimide photosensitizer was functionalized with a targeting molecule, based on folic acid, to induce selectivity of the molecule towards cancer tissues. The corresponding NIR emitting lanthanide complexes were prepared for each dendrimer. Four Yb(III)-dendrimer complexes were characterized for their photophysical and ROS production properties. All complexes demonstrated a ROS production. The dendrimer functionalized with anthraquinone and tetraphenylporphyrin photosensitizers show strong NIR emission in living cells. These new multifunctional Yb(III)-dendrimer complexes have been designed to broaden the current scope of PDT agents and of NIR optical imaging agents
APA, Harvard, Vancouver, ISO, and other styles
10

Rollakanti, Kishore Reddy. "Protoporphyrin IX Fluorescence for Enhanced Photodynamic Diagnosis and Photodynamic Therapy in Murine Models of Skin and Breast Cancer." Cleveland State University / OhioLINK, 2015. http://rave.ohiolink.edu/etdc/view?acc_num=csu1431466604.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Pdt photodynamic therapy imaging cancer"

1

Zellweger, Matthieu, Claude-André Porret, Norbert Lange, Patrice Jichlinski, Hubert van den Bergh, and Georges Wagnières. "19 PDT of non-muscle-invasive bladder cancer with Hexylester Aminolevulinate." In Imaging in Photodynamic Therapy, 385–94. Taylor & Francis Group, 6000 Broken Sound Parkway NW, Suite 300, Boca Raton, FL 33487-2742: CRC Press, 2017. http://dx.doi.org/10.1201/9781315278179-20.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Rotomskis, Ric ardas, and Giedre Streckyte. "10 Quantum dots in PDT." In Imaging in Photodynamic Therapy, 183–210. Taylor & Francis Group, 6000 Broken Sound Parkway NW, Suite 300, Boca Raton, FL 33487-2742: CRC Press, 2017. http://dx.doi.org/10.1201/9781315278179-11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Penjweini, Rozhin, Brian C. Wilson, and Timothy C. Zhu. "21 Spectroscopic imaging in prostate PDT." In Imaging in Photodynamic Therapy, 419–54. Taylor & Francis Group, 6000 Broken Sound Parkway NW, Suite 300, Boca Raton, FL 33487-2742: CRC Press, 2017. http://dx.doi.org/10.1201/9781315278179-22.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Tsubone, Tayana M., Christiane Pavani, Isabel O. L. Bacellar, and Maurício S. Baptista. "9 In search of specific PDT photosensitizers." In Imaging in Photodynamic Therapy, 149–82. Taylor & Francis Group, 6000 Broken Sound Parkway NW, Suite 300, Boca Raton, FL 33487-2742: CRC Press, 2017. http://dx.doi.org/10.1201/9781315278179-10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Ptaszek, Marcin. "2 Photochemistry and photophysics of PDT and photosensitizers." In Imaging in Photodynamic Therapy, 29–48. Taylor & Francis Group, 6000 Broken Sound Parkway NW, Suite 300, Boca Raton, FL 33487-2742: CRC Press, 2017. http://dx.doi.org/10.1201/9781315278179-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Buchholz, Julia. "Clinical Applications of Cancer PDT." In Photodynamic Therapy in Veterinary Medicine: From Basics to Clinical Practice, 139–55. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-45007-0_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Buchholz, Julia. "Basic Studies in Cancer PDT." In Photodynamic Therapy in Veterinary Medicine: From Basics to Clinical Practice, 125–37. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-45007-0_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Moore, Caroline M., and Mark Emberton. "Photodynamic Therapy for Early Prostate Cancer." In Imaging and Focal Therapy of Early Prostate Cancer, 293–306. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-49911-6_23.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Moore, Caroline M., and Mark Emberton. "Photodynamic Therapy for Early Prostate Cancer." In Imaging and Focal Therapy of Early Prostate Cancer, 283–95. Totowa, NJ: Humana Press, 2012. http://dx.doi.org/10.1007/978-1-62703-182-0_21.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Kiran, Ifrah, Naveed Akhtar Shad, Muhammad Munir Sajid, Hafiz Zeeshan Mahmood, Yasir Javed, Muhammad Sarwar, Hamed Nosrati, Hossein Danafar, and Surender K. Sharma. "X-ray Triggered Photodynamic Therapy." In Harnessing Materials for X-ray Based Cancer Therapy and Imaging, 201–16. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-04071-9_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Pdt photodynamic therapy imaging cancer"

1

Valles, Maria A. "Tetrabenzoporphyrins for PDT." In Photodynamic Therapy of Cancer II. SPIE, 1995. http://dx.doi.org/10.1117/12.199149.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Moghissi, K., and Kate Dixon. "Photodynamic therapy (PDT) for lung cancer." In Laser Florence 2004, edited by Leonardo Longo, Khalil A. Khatri, Mihail-Lucian Pascu, and Wilhelm R. Waidelich. SPIE, 2005. http://dx.doi.org/10.1117/12.660037.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Sokolov, Victor V. "First clinical results with a new drug for PDT." In Photodynamic Therapy of Cancer II. SPIE, 1995. http://dx.doi.org/10.1117/12.199168.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Didziapetriene, Janina. "Experimental studies of combination of PDT and tumor chemotherapy or." In Photodynamic Therapy of Cancer II. SPIE, 1995. http://dx.doi.org/10.1117/12.199172.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Moser, Joerg G. "Carrier systems in PDT: on the way to novel antitumor drugs." In Photodynamic Therapy of Cancer II. SPIE, 1995. http://dx.doi.org/10.1117/12.199131.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Galpern, Maria G. "Comparative analysis of different phthalocyanine photosensitizers for experimental PDT of cancer." In Photodynamic Therapy of Cancer II. SPIE, 1995. http://dx.doi.org/10.1117/12.199154.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

HUANG, ZHENG, YANG K. CHEN, HEPING XU, and FRED W. HETZEL. "INTERSTITIAL PHOTODYNAMIC THERAPY (PDT) OF SOLID TUMOR." In Proceedings of the 6th International Conference on Photonics and Imaging in Biology and Medicine (PIBM 2007). WORLD SCIENTIFIC, 2008. http://dx.doi.org/10.1142/9789812832344_0002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Roehrs, Susanne. "Fluorescence detection of MSH-receptors in melanoma as a target of hormone-directed photosensitation in PDT." In Photodynamic Therapy of Cancer II. SPIE, 1995. http://dx.doi.org/10.1117/12.199162.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Sokolov, V. V., I. G. Russakov, A. A. Teplov, E. V. Filonenko, R. V. Ul'yanov, and A. A. Bystrov. "Adjuvant photodynamic therapy (PDT) of the superficial bladder cancer." In SPIE Proceedings, edited by Andrei V. Ivanov and Mishik A. Kazaryan. SPIE, 2005. http://dx.doi.org/10.1117/12.640043.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Vervoorts, Anja. "Quantitative data on blood flow during tumor PDT obtained by laser Doppler spectroscopy in the hen's egg test system." In Photodynamic Therapy of Cancer II. SPIE, 1995. http://dx.doi.org/10.1117/12.199175.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Pdt photodynamic therapy imaging cancer"

1

Li, Haitao, Gongwei Long, and Jun Tian. Efficacy and Safety of Photodynamic Therapy for Non–muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2022. http://dx.doi.org/10.37766/inplasy2022.11.0043.

Full text
Abstract:
Review question / Objective: To comprehensively summarize the relevant clinical studies, and assess the efficacy and safety of PDT in the treatment of NMIBC. Eligibility criteria: (1) pathologically confirmed NMIBC; (2) included > 5 patients who received PDT; (3) clinical studies including randomized-controlled trials, case-control studies, and single-arm reports; (4) included efficacy and/or safety results；(5) follow-up duration > 6 months; (6) report was written in English or has a English abstract.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Pdt photodynamic therapy imaging cancer' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography